Trial · NCT04452318
Results by group292
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 292
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP | Cohort A: Placebo of R10933 + R10987 | 7.8 | Percentage of Participants | ||
| Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP | Cohort A: R10933 + R10987 | 1.4 | Percentage of Participants | ||
| Cohort B: Percentage of Participants Who Subsequently Develop Signs and Symptoms (Broad-Term) Within 14 Days of a Positive RT-qPCR at Baseline or During the EAP | Cohort B: Placebo of R10933 + R10987 | 42.5 | Percentage of Participants | ||
| Cohort B: Percentage of Participants Who Subsequently Develop Signs and Symptoms (Broad-Term) Within 14 Days of a Positive RT-qPCR at Baseline or During the EAP | Cohort B: R10933 + R10987 | 28.4 | Percentage of Participants | ||
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort A: Placebo of R10933 + R10987 | # of participants with at least one TEAE | 512 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort A: R10933 + R10987 | # of participants with at least one TEAE | 405 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort B: Placebo of R10933 + R10987 | # of participants with at least one TEAE | 88 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort B: R10933 + R10987 | # of participants with at least one TEAE | 60 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort A: Placebo of R10933 + R10987 | # of participants with at least one Grade 1 TEAE | 384 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort A: R10933 + R10987 | # of participants with at least one Grade 1 TEAE | 284 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort B: Placebo of R10933 + R10987 | # of participants with at least one Grade 1 TEAE | 61 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort B: R10933 + R10987 | # of participants with at least one Grade 1 TEAE | 51 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort A: Placebo of R10933 + R10987 | # of participants with at least one Grade 2 TEAE | 98 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort A: R10933 + R10987 | # of participants with at least one Grade 2 TEAE | 95 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort B: Placebo of R10933 + R10987 | # of participants with at least one Grade 2 TEAE | 21 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort B: R10933 + R10987 | # of participants with at least one Grade 2 TEAE | 7 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort A: Placebo of R10933 + R10987 | # of participants with at least one Grade 3 TEAE | 26 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort A: R10933 + R10987 | # of participants with at least one Grade 3 TEAE | 21 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort B: Placebo of R10933 + R10987 | # of participants with at least one Grade 3 TEAE | 6 | Participants | |
| Cohort A and Cohort B: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs) and Severity of TEAEs | Cohort B: R10933 + R10987 | # of participants with at least one Grade 3 TEAE | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04452318/results